CTOR

Healthcare Drug Manufacturers - Specialty & Generic

Citius Oncology, Inc.

$0.95

-0.06 -5.94% today

Price History

Not enough data

Key Stats

Market Cap

100.47M

Avg Volume

99,750

EPS

-$0.48

52W High

$2.25

52W Low

$0.49

Div. Yield

0.0%

Analyst Ratings

Strong Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

P/B Ratio

2.49

P/S Ratio

14.14

EV/Revenue

13.25

Margins

Gross Margin 74.8%

Operating Margin (595.6%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(126.6%)

Return on Assets

(29.1%)

Liquidity & Leverage

Current Ratio

0.73

Quick Ratio

0.29

Debt / Equity

0.25

Total Cash

16.56M

Total Debt

10.21M

About

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

citiusonc.com/overview/default.aspx